The Wall Street Journal: New omicron-specific COVID booster expected to be approved before trial data is in

by | Aug 28, 2022 | Stock Market

The Food and Drug Administration is expected to authorize new COVID-19 booster shots this week without a staple of its normal decision-making process: data from a study showing whether the shots were safe and worked in humans. The shots, modified to target the latest versions of the omicron variant, won’t have finished testing in humans when the FDA makes its decisions.

Article Attribution | Read More at Article Source

Share This